Cardiac antiplatelet therapy stands as a cornerstone in the realm of cardiovascular health management, contributing significantly to the prevention of blood clot formation—a key factor in various heart-related issues. This therapeutic approach involves the administration of medications designed to impede platelet activity, thereby mitigating the risk of blood vessel blockages and potential cardiovascular events. Beyond the widely recognized use of aspirin as a prominent antiplatelet agent, newer medications like ticagrelor and prasugrel have emerged, providing additional options for individuals with specific cardiovascular conditions. The nuanced application of antiplatelet therapy is intricately tailored to each patient's distinct medical profile, ensuring a precise and effective strategy for preserving heart health. In an era marked by continual advancements in cardiovascular medicine, the significance of cardiac antiplatelet therapy persists as a crucial element in the ongoing pursuit of comprehensive and individualized cardiovascular care.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt